PXS-6302(PXS-6302) - 药物靶点：lipoxygenase_在研适应症：瘢痕_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Topical pan-LOX inhibitor-Pharmaxis

靶点

lipoxygenase

作用机制

lipoxygenase抑制剂(脂氧合酶家族抑制剂)

治疗领域

其他疾病

在研适应症

瘢痕

非在研适应症-

原研机构

Syntara Ltd.

在研机构

Syntara Ltd.

非在研机构-

最高研发阶段临床1/2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

100 项与 PXS-6302 相关的临床结果

登录后查看更多信息

100 项与 PXS-6302 相关的转化医学

登录后查看更多信息

100 项与 PXS-6302 相关的专利（医药）

登录后查看更多信息

1

项与 PXS-6302 相关的文献（医药）

Nature Communications1区 · 综合性期刊

Topical application of an irreversible small molecule inhibitor of lysyl oxidases ameliorates skin scarring and fibrosis

1区 · 综合性期刊

ArticleOA

作者: Chaudhari, Nutan ; Findlay, Alison D ; Joshi, Amar ; Jarolimek, Wolfgang ; Stevenson, Andrew W ; Hortin, Nicole ; Rea, Suzanne ; Toshniwal, Priyanka ; Fear, Mark W ; Clemons, Tristan D ; Melton, Philip E ; Iyer, K Swaminathan ; Sayyar, Sepidar ; Wood, Fiona M ; Wallace, Gordon ; Deng, Zhenjun ; Yao, Yimin

AbstractScarring is a lifelong consequence of skin injury, with scar stiffness and poor appearance presenting physical and psychological barriers to a return to normal life. Lysyl oxidases are a family of enzymes that play a critical role in scar formation and maintenance. Lysyl oxidases stabilize the main component of scar tissue, collagen, and drive scar stiffness and appearance. Here we describe the development and characterisation of an irreversible lysyl oxidase inhibitor, PXS-6302. PXS-6302 is ideally suited for skin treatment, readily penetrating the skin when applied as a cream and abolishing lysyl oxidase activity. In murine models of injury and fibrosis, topical application reduces collagen deposition and cross-linking. Topical application of PXS-6302 after injury also significantly improves scar appearance without reducing tissue strength in porcine injury models. PXS-6302 therefore represents a promising therapeutic to ameliorate scar formation, with potentially broader applications in other fibrotic diseases.

100 项与 PXS-6302 相关的药物交易

登录后查看更多信息